Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02537587
Other study ID # GIL-1342
Secondary ID PEP-1324
Status Completed
Phase N/A
First received August 28, 2015
Last updated August 31, 2015
Start date January 2014
Est. completion date March 2014

Study information

Verified date August 2015
Source Glycemic Index Laboratories, Inc
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The purpose of this study was to determine the effect of changing the amounts of resistant starch, whey protein and sugar on the blood glucose and insulin responses elicited by energy bars. The investigators also compared the glucose and insulin responses to the rates at which the food bars were digested in-vitro (in the test tube). The investigators thought increasing resistant starch and reducing sugar would reduce the glucose and insulin responses, and that adding protein would reduce glucose and increase insulin. The investigators also thought the glucose and insulin responses in people would be related to the rate of digestion of the food bars in-vitro.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Body mass index 20.0 to 34.9 kg/m²

- Fasting serum glucose <7.0mmol/L

- Non-smoker

Exclusion Criteria:

- Known to have diabetes

- Use of medications or presence of a medical condition considered by the principal investigator to increase risk to the participant or affect the results

- Known food allergy of any kind

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Control 1
67g of control bar
Control 2
86g of control bar
15/0
66g of experimental bar 15/0
15/0LS
84g of experimental bar 15/0LS
15/5
75g of experimental bar 15/5
10/5
72g of experimental bar 10/5
10/10
80g of experimental bar 10/10

Locations

Country Name City State
Canada Glycemic Index Laboratories, Inc. Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
Glycemic Index Laboratories, Inc PepsiCo Global R&D

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incremental area under the blood glucose response curve For 3 hours after consuming each test meal No
Secondary Incremental area under the serum insulin response curve For 3 hours after consuming each test meal No
Secondary Incremental area under the blood glucose response curve For 2 hours after consuming each test meal No
Secondary Incremental area under the serum insulin response curve For 2 hours after consuming each test meal No
Secondary Insulin:Glucose area under the curve ratio Outcome 2 (incremental area under the insulin response curve for 3 hours) divided by Outcome 1 (incremental area under the glucose response curve for 3 hours) For 3 hours after consuming each test meal No
Secondary Insulin:Glucose area under the curve ratio Outcome 4 (incremental area under the insulin response curve for 2 hours) divided by Outcome 3 (incremental area under the glucose response curve for 2 hours) For 2 hours after consuming each test meal No
Secondary Insulinogenic index I30 divided by G30; where I30 is the serum insulin increment at 30 minutes and G30 is the blood glucose increment at 30 minutes; and where "increment" is defined as the concentration at 30 minutes minus the fasting concentration. 30 minutes after consuming each test meal No
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A